Active Filter(s):
Details:
The company entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a company focused on rare neuroinflammatory diseases. Acquisition provides opportunity to develop cladribine in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder.
Lead Product(s): Cladribine
Therapeutic Area: Immunology Product Name: Mavenclad
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 20, 2021
Details:
The financing will allow the company to progress CRD1 through Phase 2 proof of concept clinical development. The potential of CRD1 to address unmet medical needs in rare autoimmune disorders was identified by Chord Therapeutics‘ founder, Dr. Arthur Roach.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: CRD1
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 13, 2020